公开(公告)号：US20120102453A1

公开(公告)日：2012-04-26

申请号：US12908888

申请日：2010-10-21

Applicant: Raymond Patch ,  Rajeev Chauhan

Inventor： Raymond Patch ,  Rajeev Chauhan

IPC: G06F9/44 ,  G06F17/30

CPC classification number: G06F8/24 ,  G06F9/4488

Abstract: Architecture that enables a software object to be a multi-dimensional object by associating additional dimensions to the object. The object, in addition to the actual data dimension, is now provided with inherent object dimensions that include, but are not limited to, a localization dimension, security dimension, version dimension, personalization dimension, and attributes dimension, for example. The actual data dimension and one or more inherent object dimensions can be added, changed, or modified in realtime. A mapping component maps object relationships between an in-memory form and a tabular form storable in a database. An application programming interface facilitates interaction with the object, and the actual data dimension, and the one or more inherent object dimensions.

Abstract translation: 通过将附加维度与对象相关联来使软件对象成为多维对象的体系结构。 除了实际数据维度之外，该对象现在具有固有的对象维度，例如包括但不限于定位维度，安全维度，版本维度，个性化维度和属性维度。 实际数据维度和一个或多个固有对象维度可以实时添加，更改或修改。 映射组件映射内存中的形式与数据库中可存储的表格之间的对象关系。 应用程序编程界面便于与对象，实际数据维度以及一个或多个固有对象维度进行交互。

公开(公告)号：US20110294780A1

公开(公告)日：2011-12-01

申请号：US13114084

申请日：2011-05-24

Applicant: Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

Inventor： Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

IPC: A61K31/427 ,  C07D413/14 ,  C07D401/14 ,  C07D453/02 ,  C07D451/04 ,  C07D498/04 ,  C07D455/02 ,  C07D419/14 ,  A61K31/5377 ,  A61K31/454 ,  A61K31/496 ,  A61K31/46 ,  A61K31/439 ,  A61K31/55 ,  A61K31/541 ,  A61K31/551 ,  A61K31/4439 ,  A61K31/5383 ,  A61K31/433 ,  A61K31/4245 ,  A61K31/41 ,  A61P19/08 ,  A61P19/06 ,  A61P19/10 ,  A61P35/04 ,  A61P19/04 ,  A61P35/00 ,  A61P19/02 ,  A61P29/00 ,  A61P11/00 ,  A61P11/08 ,  A61P3/00 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  A61P3/06 ,  A61P9/00 ,  A61P9/10 ,  A61P5/48 ,  C07D417/14

CPC classification number: C07D417/06

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖症，升高的血糖水平和胰岛素抵抗。

公开(公告)号：US20060094081A1

公开(公告)日：2006-05-04

申请号：US11255147

申请日：2005-10-20

Applicant: Carsten Schubert ,  Barry Springer ,  Ingrid Deckman ,  Raymond Patch ,  Geoffrey Struble ,  Hongchang Ma ,  Celine Schalk-Hihi ,  Benjamin Brandt ,  Ioanna Petrounia

Inventor： Carsten Schubert ,  Barry Springer ,  Ingrid Deckman ,  Raymond Patch ,  Geoffrey Struble ,  Hongchang Ma ,  Celine Schalk-Hihi ,  Benjamin Brandt ,  Ioanna Petrounia

IPC: G06F19/00 ,  C07H21/04 ,  C12P21/06 ,  C12N9/12

CPC classification number: C07K14/7153 ,  C07K2299/00 ,  C07K2319/00 ,  C30B7/00 ,  G16B15/00 ,  G16B20/00 ,  G16B50/00

Abstract: The present invention includes a crystal structure of the kinase domain of c-fms and a methodology to produce diffraction quality crystals of the c-fms kinase domain by heterologous substitution of the kinase insert domain. Also included in the invention is the structure of the c-fms kinase domain in liganded form for use in the discovery of inhibitors of c-fms for the treatment of diseases caused by inappropriate activity of c-fms. The present invention includes descriptions of the X-ray diffraction patterns of the crystals. The diffraction patterns allow the three dimensional structure of c-fms to be determined at atomic resolution so that ligand binding sites on can be identified and the interactions of ligands with amino acid residues can be modeled.

Abstract translation: 本发明包括c-fms的激酶结构域的晶体结构和通过激酶插入结构域的异源取代产生c-fms激酶结构域的衍射质量晶体的方法。 本发明还包括配体形式的c-fms激酶结构域用于发现c-fms抑制剂用于治疗由c-fms的不适当活性引起的疾病的结构。 本发明包括晶体的X射线衍射图案的描述。 衍射图允许以原子分辨率确定c-fms的三维结构，从而可以鉴定配体结合位点，并且可以建模与配体与氨基酸残基的相互作用。

公开(公告)号：US08796256B2

公开(公告)日：2014-08-05

申请号：US13114084

申请日：2011-05-24

Applicant: Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

Inventor： Gilles Bignan ,  Wing Cheung ,  Micheal Gaul ,  Hui Huang ,  Xun Li ,  Raymond Patch ,  Sharmila Patel ,  Mark Player ,  Guozhang Xu ,  Bao-Ping Zhao ,  Jian Liu

IPC: C07D417/06

CPC classification number: C07D417/06

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖，升高的血糖水平和胰岛素抵抗。

公开(公告)号：US20120096048A1

公开(公告)日：2012-04-19

申请号：US12907045

申请日：2010-10-19

Applicant: Raymond Patch ,  Rajeev Chauhan

Inventor： Raymond Patch ,  Rajeev Chauhan

IPC: G06F17/30

CPC classification number: G06F16/9535

Abstract: Architecture that associates personalized information (e.g., user preferences) to an object that needs to be displayed in a custom way. The preferences are associated with the object as an inherent object dimension, in addition to the actual data (another dimension). The intrinsic actual data contained within the object itself is considered the first dimension, and additional data and/or metadata make up additional dimensions. Whenever the object is retrieved, the associated personal preferences as the inherent object dimension are returned with the object. The web developer simple uses the associated preferences to build the webpage. If no preferences were defined, the object can be configured to return with a default set of preferences.

Abstract translation: 将个性化信息（例如，用户偏好）关联到需要以自定义方式显示的对象的架构。 除了实际数据（另一个维度）之外，偏好与对象相关联，作为固有对象维度。 包含在对象本身内部的固有实际数据被认为是第一维，附加数据和/或元数据构成额外的维度。 无论何时检索对象，将返回与对象相关联的个人偏好作为固有对象维度。 Web开发人员简单使用相关的首选项来构建网页。 如果未定义任何首选项，则可以将对象配置为使用默认的首选项返回。

公开(公告)号：US20060106022A1

公开(公告)日：2006-05-18

申请号：US11233725

申请日：2005-09-23

Applicant: Jian Liu ,  Raymond Patch ,  Mark Player

Inventor： Jian Liu ,  Raymond Patch ,  Mark Player

IPC: C07D487/02 ,  A61K31/498

CPC classification number: C07D487/04

Abstract: The invention is directed to compounds of Formula I: wherein Q, Y, A are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein kinases, especially Aurora-1, Aurora-2 and Aurora-3 kinases.

公开(公告)号：US20050131022A1

公开(公告)日：2005-06-16

申请号：US10970865

申请日：2004-10-22

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  C07D223/12 ,  C07D265/30 ,  C07D279/12 ,  C07D307/68 ,  C07D405/12 ,  C07D409/12 ,  C07D45/02

CPC classification number: C07D405/12 ,  C07D207/416 ,  C07D233/90 ,  C07D307/68 ,  C07D409/12

Abstract: The invention is directed to compounds of Formulae I: wherein A, R1, R2, R3, R4, X, and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I的化合物：其中A，R 1，R 2，R 3，R 4， 说明书中列出了SUB，X和W，以及其抑制蛋白酪氨酸激酶，特别是c-fms激酶的溶剂合物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：US20050049274A1

公开(公告)日：2005-03-03

申请号：US10894940

申请日：2004-07-20

Applicant: Mark Wall ,  Mark Player ,  Raymond Patch ,  Sanath Meegalla ,  Jian Liu ,  Carl Illig ,  Wing Cheung ,  Jinsheng Chen ,  Davoud Asgari

Inventor： Mark Wall ,  Mark Player ,  Raymond Patch ,  Sanath Meegalla ,  Jian Liu ,  Carl Illig ,  Wing Cheung ,  Jinsheng Chen ,  Davoud Asgari

IPC: A61P35/00 ,  C07D215/22 ,  C07D215/227 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  C07D471/02 ,  A61K31/47 ,  C07D215/36

CPC classification number: C07D215/227 ,  C07D401/04 ,  C07D409/04 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D471/04 ,  Y02P20/582

Abstract: The invention is directed to compounds of Formulae I and II: wherein R1, R2, R3, R5, R6, Y1, Y2, Y3, Y4 and X are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I和II的化合物：其中R 1，R 2，R 3，R 5，R 6，Y 1，Y 2， 3>，Y 4和X在说明书中列出，以及其抑制蛋白酪氨酸激酶，特别是c-fms激酶的溶剂合物，水合物，互变异构体或其药学上可接受的盐。

公开(公告)号：US20050004112A1

公开(公告)日：2005-01-06

申请号：US10831216

申请日：2004-04-26

Applicant: Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

Inventor： Mark Player ,  Nand Baindur ,  Benjamin Brandt ,  Naresh Chadha ,  Raymond Patch ,  Davoud Asgari ,  Taxiarchis Georgiadis

IPC: A61K31/16 ,  A61K31/195 ,  A61K31/452 ,  A61K31/4545 ,  A61K31/55 ,  A61P35/00 ,  C07D207/34 ,  C07D207/42 ,  C07D213/81 ,  C07D223/12 ,  C07D231/16 ,  C07D231/38 ,  C07D261/18 ,  C07D265/02 ,  C07D265/30 ,  C07D279/12 ,  C07D295/14 ,  C07D307/68 ,  C07D307/71 ,  C07D307/72 ,  C07D401/12 ,  C07D405/00 ,  C07D405/12 ,  C07D491/04

CPC classification number: C07D213/81 ,  C07D231/38 ,  C07D265/02 ,  C07D307/68 ,  C07D307/71 ,  C07D405/12 ,  C07D491/04

Abstract: The invention is directed to compounds of Formulae I, II and III: wherein A, R1, R2, R3, R4, X, Y and W are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase.

Abstract translation: 本发明涉及式I，II和III的化合物：其中A，R 1，R 2，R 3，R 4，X，Y和W在说明书中列出，以及溶剂合物，水合物，互变异构体或其药学上可接受的盐 ，抑制蛋白酪氨酸激酶，特别是c-fms激酶。

公开(公告)号：US08344009B2

公开(公告)日：2013-01-01

申请号：US12899812

申请日：2010-10-07

Applicant: Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

Inventor： Michael Gaul ,  Alexander Kim ,  Lily Lee Searle ,  Raymond Patch ,  Dionisois Rentzeperis ,  Guozhang Xu ,  Xizhen Zhu

IPC: A61K31/426 ,  C07D277/04

CPC classification number: C07D277/34 ,  C07D263/44

Abstract: The present invention relates to compounds of Formula (I), methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury/loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.

Abstract translation: 本发明涉及式（I）化合物，制备这些化合物的方法，组合物，中间体及其衍生物，用于治疗包括但不限于强直性脊柱炎，动脉粥样硬化，关节炎（如类风湿性关节炎，感染性关节炎，儿童期 关节炎，牛皮癣关节炎，反应性关节炎），骨相关疾病（包括与骨形成相关的疾病），乳腺癌（包括对抗雌激素治疗无反应的那些），心血管疾病，软骨相关疾病（如软骨损伤/损失， 软骨变性和与软骨形成相关的软骨变性，软骨发育不全，软骨肉瘤，慢性背部损伤，慢性支气管炎，慢性炎症性气道疾病，慢性阻塞性肺病，糖尿病，能量稳态障碍，痛风，假性血糖，脂质障碍，代谢综合征，多发性 骨髓瘤，肥胖症，骨关节炎，成骨不全，骨质溶解骨 骨质疏松症，骨质疏松症，佩吉特氏病，牙周病，风湿性多肌痛，莱特综合征，重复性应激损伤，高血糖，升高的血糖水平和胰岛素抵抗。